Published in Science on September 10, 1976
Ultra Low Dose Interleukin-2 in Healthy Volunteers | NCT01445561
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer | NCT00005655
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med (1979) 7.20
Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med (1983) 5.82
The functional relationship of the interleukins. J Exp Med (1980) 5.62
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med (1984) 5.26
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci U S A (1984) 4.78
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A (1985) 4.19
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci U S A (1983) 4.01
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells. Proc Natl Acad Sci U S A (1985) 3.95
Long-term culture of human antigen-specific cytotoxic T-cell lines. J Exp Med (1978) 3.80
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res (1983) 3.44
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med (1978) 3.18
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med (1985) 3.04
Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci U S A (1983) 3.01
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J Exp Med (1983) 2.82
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol (1986) 2.76
Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med (1984) 2.74
Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol (1981) 2.72
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
Cytokines in asthma. Thorax (1999) 2.64
The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology (2005) 2.62
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J (1989) 2.62
Primary structure analysis of the major internal protein p24 of human type C T-cell leukemia virus. Proc Natl Acad Sci U S A (1982) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. Proc Natl Acad Sci U S A (1985) 2.46
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol (2011) 2.44
High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med (1986) 2.37
Prostaglandin E inhibits the production of human interleukin 2. J Exp Med (1982) 2.34
Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A (1994) 2.31
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. Proc Natl Acad Sci U S A (1984) 2.17
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. Proc Natl Acad Sci U S A (1984) 2.12
Purification and partial sequence analysis of human T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.09
Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells. J Exp Med (1985) 1.99
Characterization of the human granulocyte-macrophage colony-stimulating factor promoter region by genetic analysis: correlation with DNase I footprinting. Mol Cell Biol (1988) 1.97
Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett (2007) 1.91
Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol Cell Biol (1995) 1.89
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci U S A (1985) 1.80
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother (2005) 1.78
T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci U S A (1984) 1.77
Molecular anatomy of viral persistence. J Virol (1991) 1.75
B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med (1983) 1.73
T cell growth factor abrogates concanavalin A-induced suppressor cell function. J Exp Med (1981) 1.68
Characterization of cDNA clones for human myeloperoxidase: predicted amino acid sequence and evidence for multiple mRNA species. Nucleic Acids Res (1987) 1.67
Specific binding of radioiodinated granulocyte-macrophage colony-stimulating factor to hemopoietic cells. EMBO J (1985) 1.63
The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J (1996) 1.60
Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med (1981) 1.59
Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med (1990) 1.56
Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells. Proc Natl Acad Sci U S A (1984) 1.51
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Association of p56lck with IL-2 receptor beta chain is critical for the IL-2-induced activation of p56lck. EMBO J (1993) 1.48
Purification to homogeneity and partial characterization of interleukin 2 from a human T-cell leukemia. Proc Natl Acad Sci U S A (1984) 1.47
Isolation of human immunodeficiency virus-related simian immunodeficiency viruses from African green monkeys. Proc Natl Acad Sci U S A (1989) 1.47
Interleukin 2 receptor expression in unstimulated murine splenic T cells. Localization to L3T4+ cells and regulation by non-H-2-linked genes. J Exp Med (1986) 1.44
Antigen-specific human T-cell clones: development of clones requiring HLA-DR-compatible presenting cells for stimulation in presence of antigen. Proc Natl Acad Sci U S A (1981) 1.44
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol (2006) 1.43
Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A (2006) 1.41
Human spleen as a source of T cell growth factor. Clin Exp Immunol (1981) 1.40
Nucleotide sequence of mouse IL-2 receptor cDNA and its comparison with the human IL-2 receptor sequence. Nucleic Acids Res (1985) 1.40
Organization and structure of the mouse interleukin-2 gene. Nucleic Acids Res (1984) 1.39
Long-term culture and cloning of nontransformed human B lymphocytes. J Exp Med (1981) 1.39
Human T-cell leukemia-lymphoma virus (HTLV): cloning of an integrated defective provirus and flanking cellular sequences. Proc Natl Acad Sci U S A (1983) 1.38
Purification and chemical characterization of the receptor for interleukin 2 from activated human T lymphocytes and from a human T-cell lymphoma cell line. Proc Natl Acad Sci U S A (1984) 1.37
Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1982) 1.37
Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med (1985) 1.34
Biological significance of soluble IL-2 receptor. Mediators Inflamm (1993) 1.33
Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A (1995) 1.32
Autocrine growth stimulation of a human T-cell lymphoma line by interleukin 2. Proc Natl Acad Sci U S A (1985) 1.32
Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide. Proc Natl Acad Sci U S A (1987) 1.31
Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep (2007) 1.31
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol (1994) 1.29
Molecular cloning of a functional bovine interleukin 2 cDNA. Proc Natl Acad Sci U S A (1986) 1.29
Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis (2000) 1.26
Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2. J Exp Med (1986) 1.26
Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med (1995) 1.25
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Generation of an interleukin-I-like lymphocyte-stimulating factor at inflammatory sites: correlation with the infiltration of polymorphonuclear leucocytes. Br J Exp Pathol (1984) 1.24
c-fos gene induction by interleukin 2: identification of the critical cytoplasmic regions within the interleukin 2 receptor beta chain. Proc Natl Acad Sci U S A (1992) 1.23
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood (1979) 6.01
Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial. Lancet (2000) 6.00
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol (1981) 4.27
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Long-term culture of human antigen-specific cytotoxic T-cell lines. J Exp Med (1978) 3.80
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
T-cell growth factor-mediated T-cell proliferation. Ann N Y Acad Sci (1979) 3.16
Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest (1997) 2.98
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med (1979) 2.80
HIV/HTLV gene nomenclature. Nature (1988) 2.72
Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol (1981) 2.72
Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood (1981) 2.58
Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody. J Exp Med (1981) 2.47
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
T-cell growth factor and the culture of cloned functional T cells. Adv Immunol (1981) 2.09
Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol (1989) 2.00
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest (1996) 1.92
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension (1999) 1.82
Complications of cardiac catheterization in the current era: a single-center experience. Catheter Cardiovasc Interv (2001) 1.72
Functional and molecular characteristics of T-cell growth factor. Mol Immunol (1980) 1.66
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A (1992) 1.59
Immortalized hemopoietic cells with stem cell properties. Immunity (1994) 1.55
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation (2001) 1.54
Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 1.51
Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med (1990) 1.51
Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol (1998) 1.48
Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A (1986) 1.43
Specific release of neutrophillic- and eosinophilic-stimulating factors from sensitized lymphocytes. Blood (1976) 1.43
The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br J Surg (1985) 1.42
The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study. Br J Dermatol (2012) 1.42
Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens (1999) 1.42
Effects of leptin on insulin sensitivity in normal rats. Endocrinology (1997) 1.42
The challenge of valve surgery in a developing population. J Heart Valve Dis (1993) 1.40
A randomly amplified polymorphic DNA marker specific for the Bacillus cereus group is diagnostic for Bacillus anthracis. Appl Environ Microbiol (1999) 1.40
Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 1.39
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J Immunol (1989) 1.39
Prophylactic cranial irradiation for small-cell lung cancer: long-term results. Clin Oncol (R Coll Radiol) (1989) 1.39
Accelerated degeneration of aortic homograft in an infant. J Thorac Cardiovasc Surg (1994) 1.39
Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1. J Endocrinol Invest (2003) 1.39
Repetitive structure in the long-terminal-repeat element of a type II human T-cell leukemia virus. Proc Natl Acad Sci U S A (1984) 1.39
Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol (1986) 1.37
Release of colony-stimulating activity from thymus-derived lymphocytes. J Clin Invest (1975) 1.37
Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1982) 1.37
The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) (2001) 1.35
Shared care: a review of the literature. Fam Pract (1996) 1.34
Detection of HLA-DRw (Ia-like) antigens on human T lymphocytes grown in tissue culture. J Immunol (1979) 1.33
Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood (1996) 1.32
Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth. J Immunol (1991) 1.32
Sympathetic and cardiorenal actions of leptin. Hypertension (1997) 1.32
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Molecular evolution of nitrogen fixation: the evolutionary history of the nifD, nifK, nifE, and nifN genes. J Mol Evol (2000) 1.30
Nomenclature of eukaryotic DNA polymerases. Science (1975) 1.30
Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo. J Clin Invest (1992) 1.29
Functional characterization of a novel hematopoietic stem cell and its place in the c-Kit maturation pathway in bone marrow cell development. Immunity (1999) 1.28
Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proc Natl Acad Sci U S A (1992) 1.24
Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J Exp Med (1988) 1.24
ABC of breast diseases. Management of regional nodes in breast cancer. BMJ (1994) 1.23
Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation. J Virol (2001) 1.23
Nomenclature of eukaryotic DNA polymerases. Eur J Biochem (1975) 1.20
Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood (1988) 1.18
Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP-1 cells. J Exp Med (1990) 1.18
ABC of breast diseases. Breast cancer. BMJ (1994) 1.17
Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun (2000) 1.16
Preferential stimulation of rabbit alpha globin mRNA translation by a cap-binding protein complex. Biochim Biophys Acta (1984) 1.12
Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex. Mol Cell Biol (1990) 1.11
Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii. Proc Natl Acad Sci U S A (1986) 1.11
Association of protein kinase C activation with IL 2 receptor expression. J Immunol (1986) 1.11
Release of colony-stimulating factor from monocytes by endotoxin and polyinosinic-polycytidylic acid. J Lab Clin Med (1974) 1.10
Formation of fetal rat cardiac cell clones by retroviral transformation: retention of select myocyte characteristics. J Mol Cell Cardiol (1993) 1.10
Tumor necrosis factor alpha directly and indirectly regulates hematopoietic progenitor cell proliferation: role of colony-stimulating factor receptor modulation. J Exp Med (1992) 1.10
Cytokine mRNA expression in human platelets and a megakaryocytic cell line and cytokine modulation of platelet function. Cytokine (1997) 1.09
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol (1988) 1.09
The case for a family of reverse transcriptase viruses: Retraviridae. Intervirology (1974) 1.09
Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. Am J Physiol (1994) 1.09
Gamma-interferon-induced activation of latent transforming growth factor-beta by human monocytes. Ann N Y Acad Sci (1990) 1.08
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol (1989) 1.08
Aortic valve replacement with freehand autologous pericardium. J Thorac Cardiovasc Surg (1995) 1.08
Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood (1985) 1.07
Nitrogen fixation genes in an endosymbiotic Burkholderia strain. Appl Environ Microbiol (2001) 1.06
Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. Blood (1990) 1.05
BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia (2000) 1.05
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood (1996) 1.05
Two forms of transforming growth factor-beta are equally potent selective growth inhibitors of early murine hematopoiesis. Ann N Y Acad Sci (1990) 1.04
Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma. J Immunol (1986) 1.04
Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood (1990) 1.04
Extracellular human T-cell lymphotropic virus type I Tax protein induces cytokine production in adult human microglial cells. Ann Neurol (1994) 1.03